Company Overview and News

 
Why I Bought More Apple Stock Friday

6h seekingalpha
The panic was thanks to TSM's earnings report and Morgan Stanley’s issue of caution towards iPhone sales.
Upvote Downvote

 
MagnaChip Semiconductor: A Stock Under $10 With 40% Upside, But Also Downside

9h seekingalpha
MagnaChip's competitive strengths are poised to help drive growth for the company's products for multiple applications.
Upvote Downvote

 
ADT: Plenty Of Room To Run Following Its Recent IPO

2018-04-21 seekingalpha
I admit, I’ve been a dinosaur when it comes to many things, among them home security monitoring. For going on 20 years, I’ve paid a modest monthly fee for someone at a central monitoring station to call the police and me if a sensor in my home has been tripped indicating a possible intruder.
Upvote Downvote

 
Roku's Long-Term Potential Is Unaffected By Amazon And Best Buy

2018-04-20 seekingalpha
TV is a commoditized business, it's not surprising to me that Insignia wants to differentiate. TCL is currently the dominant Roku TV brand.
Upvote Downvote

 
Chinese Tech Increasingly A Match For U.S. Big Tech. Should We Worry?

2018-04-20 seekingalpha
The rise of Chinese high-tech companies has produced the specter of Chinese domination of the industries of the future.
Upvote Downvote

 
Facebook: Oh Snap!

2018-04-18 seekingalpha
Facebook has been dealt a sentiment-induced blow when revelation about their privacy issues re-surfaced over the last few weeks.
Upvote Downvote

 
Coherent: Time To Buy

2018-04-18 seekingalpha
Looking at Coherent (COHR) over the last three months has been an interesting and somewhat puzzling experience. Since hitting a 52-week (and all-time) high of $329 back in January 2018, the stock has lost 45% of its value as of Tuesday's close of $181.62. Many of the explanations I've come across blame lackluster OLED adoption for the decline, and COHR falling in lockstep with Universal Display (OLED) seems to corroborate that claim.
Upvote Downvote

 
What Can We Expect From Lam Research's Q3 Earnings Call

2018-04-16 seekingalpha
Lam Research will announce Q3 2018 and the company has set revenue guidance of $2.85 billion.
Upvote Downvote

 
FANG Has No Apple

2018-04-16 seekingalpha
Based on the common characteristics of the original FANG group, I conclude that the resounding answer is no.
Upvote Downvote

2
Lithium Investing: Capital Continues To Flow Into Lithium Assets As Demand Rises

2018-04-16 seekingalpha
Battery production continues to climb as automakers bring new options to market; new energy vehicle sales figures continue to rise.
Upvote Downvote

2
Will A BlackBerry Lawsuit End Snapchat?

2018-04-13 seekingalpha
BB recently won a $940MM settlement from QCOM. BB wants to monetize its patent portfolio and Snapchat could be its next victim.
Upvote Downvote

 
Insights From Our March 2018 Visits To IT Hardware Makers In China/Taiwan/Japan

2018-04-11 seekingalpha
Silicon wafers to remain in short supply; Chinese chipmakers unfit to build mass-production lines in 2018.
Upvote Downvote

 
Apple: Dividend Hike Ahead

2018-04-09 seekingalpha
The dividend hike will probably be higher this year than last year due to repatriation of overseas cash.
Upvote Downvote

 
Why Memory Chips Won't Be Impacted By A Trade War In One Chart

2018-04-09 seekingalpha
Current bravado between the U.S. and China that could spark a trade war could also impact U.S. manufacturers of memory chips.
Upvote Downvote

 
Valuing GameStop In A Positive Scenario

2018-04-09 seekingalpha
Shares of GameStop are in free fall as the market is focusing on the recent weakness and is discounting a fast decline in the core business.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: Y74718100